Emperra Appoints Christian Krey as New CEO
News Feb 13, 2014
EMPERRA® GmbH E-Health Technologies has announced the appointment of Dr. Christian Krey as Managing Director and CEO. Dr. Krey has many years of experience in the field of diabetes mellitus and was previously employed as Business Unit Manager at a Johnson & Johnson subsidiary.
Prior to that, Dr. Krey held various positions in the field of diabetes at Lilly, Berlin Chemie and A. Menarini Diagnostics. In the future, Dr. Mertens, who has held the position of Managing Director and CEO for the past three years, will be assuming the role of VP Business Development. Dr. Schildt continues to be the responsible Managing Director for the fields of Medicine and Technology.
With ESYSTA®, the company EMPERRA® GmbH E-Health Technologies has developed and launched the world's first GSM- and Web-based telemedical total management system for diabetes mellitus type 1 and 2 requiring insulin.
The ESYSTA® portfolio is totally CE-certified according to the Medical Product Act (MPG) in hardware and software and thus approved for marketing and sales in the EU. Furthermore, data protection and IT security requirements are fulfilled by the ESYSTA® system.
Parts of the ESYSTA® portfolio are already listed in the range of services of statutory health insurance (GKV) and thus approved for extensive prescription by physicians.
For the first time, ESYSTA® enables all data such as insulin dose, blood glucose readings and carbohydrate units are completely recorded. Via cell phone and with the assistance of a Web-based assessment platform, all relevant data are always available on computers, tablets and smart phones (Android®/iOS®) not only to patients/family members but also to physicians in private practice and clinics.
ESYSTA® significantly improves diagnostics, therapy, patient guidance, patient compliance, self-empowerment and quality of life. The ESYSTA® product system additionally leads to a significant cost reduction for statutory health funds and reimbursers for the highly-prevalent, cost-intensive chronic illness, "diabetes mellitus".
With the patented ESYSTA® pen, for the first time worldwide, there is now an insulin pen that uses all insulins of major insulin suppliers and can thus be used for all patients without having to change the insulin therapy. The ESYSTA® insulin pen ensures that all insulin doses administered by patients are recorded, transmitted via wireless and documented in the ESYSTA® portal.
Dr. Klaus Stöckemann, Chairman of the Advisory Board of EMPERRA® GmbH and Managing Director of Peppermint Venture Partners explains: "With Dr. Krey, we are elated to have recruited an experienced manager for Emperra from the field of diabetes. At the same time, we also owe great gratitude to Dr. Mertens for his work over the past three years and are pleased that he will continue to be a part of the company in his new important role."
Dr. Christian Krey, Managing Director and CEO of EMPERRA® GmbH explains: “I am very happy to be at Emperra and to utilize my many years of experience in the field of diabetes, in order to position in the market and further develop the ESYSTA® system. This system is unique and will help improve the care for persons with diabetes. For the first time, it enables all stakeholders to be involved."
Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them. This provides an insight into the brain degeneration that defines the rare dementia termed primary progressive aphasia.
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE